Clinical Trials
Harbour BioMed Forecasts Record H1 2026 Profit as Strategic Partnerships Drive Growth
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutic...
July 27, 2026 | Company results
ArkBio Completes Dosing in Phase I Trial of Long-Acting Influenza Prevention Candidate AK0406
Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that all cohorts of healthy volunteers have been dosed in an Australian Phase I trial w...
July 27, 2026 | News
Laminar Pharma Completes Pivotal Phase 2b/3 Trial of LAM561 in Newly Diagnosed Glioblastoma
Laminar Pharma, a leader in the development of innovative therapies based on a novel membrane lipid therapy approach, announced that the last patient has c...
July 27, 2026 | News
Ribo’s Vortosiran Achieves 92% FXI Activity Reduction in Phase 2a Coronary Artery Disease Study
Suzhou Ribo Life Science Co., Ltd. (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo") today announce at C...
July 24, 2026 | News
Alebund Doses First Participant in Global Phase IIb Trial of AP306 for Hyperphosphatemia
Alebund Pharmaceuticals a renal-focused biopharmaceutical company, announced that the first participant has been randomized and dosed in the global Phase I...
July 23, 2026 | News
Lundbeck Completes Patient Randomisation in Phase III Bexicaserin Trial for Rare Epilepsies
DEEp OCEAN is a global trial designed to evaluate the investigational molecule bexicaserin for the treatment of seizures associated with DEEs, a diverse ...
July 22, 2026 | News
China Approves SystImmune’s Iza-bren for Recurrent or Metastatic Esophageal Cancer
SystImmune Inc. announced that its parent company, Sichuan Biokin Pharmaceutical Co., Ltd. (Biokin), has received regulatory approval from China's Na...
July 21, 2026 | News
Dimerix Acquires Phase II-Ready DMX-652 to Expand Kidney Disease Pipeline
Dimerix acquires Phase 2-ready asset, DMX-652 - with potential for rapid advancement into a Phase 2 clinical study under an open US Investigational New D...
July 20, 2026 | News
Neurizon Completes Rapid Phase II/III NUZ-001 Enrolment for ALS with Results Expected in Q2 2027
250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY AL...
July 20, 2026 | News
Telix Advances Illuccix Towards Japan Approval After Completing Phase III Patient Enrollment
Completed enrollment of 105 patients in Phase 3 registration study of TLX591-Px (Illuccix®) for prostate cancer imaging in Japan. The study data wil...
July 20, 2026 | News
Merck Invests €25M to Expand BioReliance Testing Capabilities in Europe
• New 2,000-square-meter facility expands Merck’s global testing network with commercial drug substance and drug product release testing a...
July 17, 2026 | News
Harbour BioMed, Kelun-Biotech Secure China IND Approval for Bispecific Antibody in Asthma
Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, o...
July 17, 2026 | News
Telix Takes Next-Generation PSMA Radioligand Therapy into Earlier Prostate Cancer Treatment
First patients dosed in OPTIMAL-e[1] Phase 2 study evaluating TLX597-Tx for metastatic hormone-sensitive prostate cancer at St Vincent's Hospital Sy...
July 17, 2026 | News
Lynk Pharmaceuticals Completes Phase III Enrolment for Zemprocitinib in Ankylosing Spondylitis
Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, ...
July 16, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
